Dissecting the Genetic Variations Associated with Response to First-Line Chemotherapy in Patients with Small Cell Lung Cancer: A Retrospective Cohort Study

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This study found that first-line treatment with docetaxel and carboplatin was safe and effective for elderly patients with advanced non-selective non-small-cell lung cancer, showing an overall efficacy rate of 47.87%.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

This study assessed pharmacogenomic variants and chemotherapy-related toxicity profiles in Tanzanian children with cancer, reporting notable genetic diversity that may influence toxicity but did not evaluate genotype-toxicity associations.

In this study involving South African breast cancer patients, researchers identified certain genetic variations in cytochrome P450 and other enzymes potentially linked to differences in tamoxifen treatment outcomes, suggesting a need for more comprehensive pharmacogenomic studies to optimize therapy in African populations.